Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study

Area of Science:

• Endocrinology
• Urology
• Sexual Medicine

Background:

• Erectile dysfunction (ED) is often linked to declining sexual activity and potentially lower testosterone levels.
• Understanding the long-term hormonal changes associated with treating ED is crucial.

Purpose of the Study:

• To determine if hormonal changes observed with the resumption of sexual activity are sustained long-term.
• To investigate the effects of 12-month tadalafil treatment on sex hormones and erectile function.

Main Methods:

• 20 male patients with ED received tadalafil (10-20 mg) on demand for 12 months.
• Primary endpoints included changes in total testosterone, free testosterone, and estradiol levels.
• Secondary endpoints measured erectile function using the International Index of Erectile Function-5 (IIEF-5) scores.

Main Results:

• Tadalafil was safe and well-tolerated, with no treatment discontinuations.
• Estradiol levels significantly decreased, leading to an increased testosterone:estradiol ratio (P=0.05).
• Significant improvement in IIEF-5 scores (P<0.0001) was observed, with estradiol reduction more pronounced in lean individuals.

Conclusions:

• Sustained improvement in erectile function after 12 months of tadalafil is linked to an elevated testosterone:estradiol ratio.
• The reduction in estradiol levels may be a key factor in regulating erectile function.
• Chronic tadalafil use might influence androgen-estrogen interactions and aromatase activity, impacting erectile function.